Decoy Therapeutics (NASDAQ:DCOY) Short Interest Update

Decoy Therapeutics (NASDAQ:DCOY) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 156,313 shares, a growth of 7,850.8% from the June 15th total of 1,966 shares. Approximately 29.9% of the shares of the company are sold short. Based on an average daily volume of 1,217,647 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.00.

Decoy Therapeutics Stock Performance

NASDAQ:DCOY traded down $0.35 during mid-day trading on Friday, hitting $5.91. 18,981 shares of the company traded hands, compared to its average volume of 201,425. The company has a fifty day moving average of $6.42. The company has a market cap of $3.13 million, a price-to-earnings ratio of -0.06 and a beta of 0.59. Decoy Therapeutics has a one year low of $4.32 and a one year high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last posted its quarterly earnings data on Friday, May 8th. The company reported ($4.18) earnings per share for the quarter. As a group, equities research analysts expect that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.